Currently, there are 108.10M common shares owned by the public and among those 97.35M shares have been available to trade.
The company’s stock has a 5-day price change of 68.36% and 78.21% over the past three months. NVCR shares are trading 99.93% year to date (YTD), with the 12-month market performance up to 143.28% higher. It has a 12-month low price of $11.66 and touched a high of $24.74 over the same period. NVCR has an average intraday trading volume of 1.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 64.41%, 77.15%, and 72.82% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of NovoCure Ltd (NASDAQ: NVCR) shares accounts for 85.89% of the company’s 108.10M shares outstanding.
It has a market capitalization of $3.29B and a beta (3y monthly) value of 0.75. The earnings-per-share (ttm) stands at -$1.39. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.41% over the week and 7.01% over the month.
Earnings per share for the fiscal year are expected to increase by 32.61%, and -23.99% over the next financial year.
Looking at the support for the NVCR, a number of firms have released research notes about the stock. Evercore ISI stated their Outperform rating for the stock in a research note on Dec-03-24, with the firm’s price target at $18-$30. H.C. Wainwright coverage for the NovoCure Ltd (NVCR) stock in a research note released on October 16, 2024 offered a Buy rating with a price target of $30. JP Morgan was of a view on November 20, 2023 that the stock is Neutral, while H.C. Wainwright gave the stock Neutral rating on August 28, 2023, issuing a price target of $85- $25. Piper Sandler on their part issued Overweight rating on August 08, 2023.
